Beth Christian

2.7k total citations
84 papers, 979 citations indexed

About

Beth Christian is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, Beth Christian has authored 84 papers receiving a total of 979 indexed citations (citations by other indexed papers that have themselves been cited), including 71 papers in Pathology and Forensic Medicine, 41 papers in Genetics and 39 papers in Oncology. Recurrent topics in Beth Christian's work include Lymphoma Diagnosis and Treatment (71 papers), Chronic Lymphocytic Leukemia Research (41 papers) and Viral-associated cancers and disorders (17 papers). Beth Christian is often cited by papers focused on Lymphoma Diagnosis and Treatment (71 papers), Chronic Lymphocytic Leukemia Research (41 papers) and Viral-associated cancers and disorders (17 papers). Beth Christian collaborates with scholars based in United States, Canada and Poland. Beth Christian's co-authors include Kristie A. Blum, John C. Byrd, Thomas S. Lin, Kami J. Maddocks, Robert A. Baiocchi, Michael R. Grever, Joseph M. Flynn, Nancy L. Bartlett, Pierluigi Porcu and Stephen M. Ansell and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Beth Christian

74 papers receiving 966 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Beth Christian United States	18	682	521	404	207	172	84	979
James Q. Wang Australia	9	579 0.8×	392 0.8×	273 0.7×	288 1.4×	106 0.6×	12	904
Amanda Copeland United States	15	558 0.8×	623 1.2×	315 0.8×	166 0.8×	99 0.6×	36	1.2k
Magdalena Klánová Czechia	12	397 0.6×	346 0.7×	252 0.6×	130 0.6×	96 0.6×	38	721
Tim E. Hawkins United States	11	614 0.9×	497 1.0×	320 0.8×	88 0.4×	137 0.8×	15	882
Herbert Eradat United States	17	531 0.8×	257 0.5×	564 1.4×	270 1.3×	46 0.3×	60	966
Jennifer E. Amengual United States	15	450 0.7×	408 0.8×	137 0.3×	214 1.0×	63 0.4×	87	1.1k
Papiya Sinha United States	7	474 0.7×	634 1.2×	129 0.3×	465 2.2×	82 0.5×	9	1.0k
S. Öhl Germany	13	378 0.6×	234 0.4×	264 0.7×	179 0.9×	84 0.5×	19	778
Alicja Gruszka Italy	20	380 0.6×	259 0.5×	378 0.9×	112 0.5×	58 0.3×	36	945
Jerzy Z. Błoński Poland	21	642 0.9×	291 0.6×	797 2.0×	403 1.9×	18 0.1×	75	1.2k

Countries citing papers authored by Beth Christian

Since Specialization

Citations

This map shows the geographic impact of Beth Christian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Beth Christian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Beth Christian more than expected).

Fields of papers citing papers by Beth Christian

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Beth Christian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Beth Christian. The network helps show where Beth Christian may publish in the future.

Co-authorship network of co-authors of Beth Christian

This figure shows the co-authorship network connecting the top 25 collaborators of Beth Christian. A scholar is included among the top collaborators of Beth Christian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Beth Christian. Beth Christian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Torka, Pallawi, Natalie S. Grover, Timothy Voorhees, et al.. (2025). Impact of Age on Biology, Presentation and Outcomes in Marginal Zone Lymphoma: Results From a Multicenter Cohort Study. Hematological Oncology. 43(3). e70087–e70087. 1 indexed citations

Cheson, Bruce D., Nancy L. Bartlett, B Knopf, et al.. (2025). Brentuximab vedotin and nivolumab for untreated patients with Hodgkin lymphoma: long-term results. Blood Advances. 9(15). 3750–3753. 1 indexed citations

Silberman, Pedro C., Yazeed Sawalha, Beth Christian, et al.. (2024). Secondary myeloid malignancy after CAR T cell therapy for non-Hodgkin lymphoma (NHL).. Journal of Clinical Oncology. 42(16_suppl). 7033–7033. 2 indexed citations

Strati, Paolo, Morton Coleman, Sonali M. Smith, et al.. (2024). Acalabrutinib alone or in combination with rituximab for follicular lymphoma: An open‐label study. British Journal of Haematology. 205(6). 2248–2253. 2 indexed citations

Epperla, Narendranath, Natalie S. Grover, Pallawi Torka, et al.. (2024). Addition of Monoclonal Protein to MALT-IPI Improved Identification of MALT Patients at High Risk of Progression with Current First-Line Therapies. Blood. 144(Supplement 1). 398–398.

Epperla, Narendranath, Natalie S. Grover, Pallawi Torka, et al.. (2024). Evaluation of Risk Factors for Histological Transformation in Patients with Marginal Zone Lymphoma (MZL): Results from a Multicenter Cohort Study. Blood. 144(Supplement 1). 2344–2344.

Epperla, Narendranath, Geoffrey Shouse, Natalie S. Grover, et al.. (2023). Impact of Maintenance Rituximab Following First-Line Systemic Therapy on Outcomes in Patients with Marginal Zone Lymphoma: Real-World Evidence from 10 US Centers. Blood. 142(Supplement 1). 5147–5147.

Sawalha, Yazeed, Brian Hess, Audrey M. Sigmund, et al.. (2023). Zanubrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results from a Phase 1b Clinical Trial. Blood. 142(Supplement 1). 6226–6226.

Grover, Natalie S., Pallawi Torka, Marcus P. Watkins, et al.. (2023). Impact of circulating lymphoma cells at diagnosis on outcomes in patients with marginal zone lymphoma: a multicenter cohort study. Blood Advances. 7(22). 6839–6843. 3 indexed citations

10.

Husain, Marium, Muhammad Salman Faisal, Dionisia Quiroga, et al.. (2023). A cancer disparities curriculum in a hematology/oncology fellowship program. BMC Medical Education. 23(1). 773–773. 2 indexed citations

11.

Epperla, Narendranath, Qiuhong Zhao, Tamara K. Moyo, et al.. (2023). Outcomes of marginal zone lymphoma treated with ibrutinib in the first-line setting in the United States: a real-world analysis. Blood Advances. 8(3). 549–552.

12.

Faisal, Muhammad Salman, Walter Hanel, Timothy Voorhees, et al.. (2023). Outcomes associated with allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma in the era of novel agents. Cancer Medicine. 12(7). 8228–8237. 2 indexed citations

13.

Nalin, Ansel P., Qiuhong Zhao, Timothy Voorhees, et al.. (2023). Impact of circulating lymphoma cells at diagnosis on outcomes in patients with Waldenstrom macroglobulinemia. Frontiers in Oncology. 13. 1264387–1264387. 1 indexed citations

14.

Epperla, Narendranath, Rui Li, Pallawi Torka, et al.. (2022). Early Relapse within 24 Months after Frontline Systemic Therapy (POD24) Is Associated with Worse Survival in Patients with Marginal Zone Lymphoma: A US Multisite Study. Blood. 140(Supplement 1). 1926–1928. 2 indexed citations

15.

Advani, Ranjana H., Alison J. Moskowitz, Nancy L. Bartlett, et al.. (2021). Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results. Blood. 138(6). 427–438. 116 indexed citations

16.

Cheson, Bruce D., Nancy L. Bartlett, Betsy LaPlant, et al.. (2020). Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial. The Lancet Haematology. 7(11). e808–e815. 66 indexed citations

17.

Hernandez‐Ilizaliturri, Francisco J., Ian W. Flinn, John Kuruvilla, et al.. (2020). A Phase I Pharmacokinetic (PK) and Safety Study of Trph-222 in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R NHL): Dose-Escalation Results. Blood. 136(Supplement 1). 41–42. 12 indexed citations

18.

Maly, Joseph, Beth Christian, Xiaohua Zhu, et al.. (2017). A Phase I/II Trial of Panobinostat in Combination With Lenalidomide in Patients With Relapsed or Refractory Hodgkin Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 17(6). 347–353. 23 indexed citations

19.

Christian, Beth, Michael R. Grever, John C. Byrd, & Thomas S. Lin. (2009). Flavopiridol in Chronic Lymphocytic Leukemia: A Concise Review. Clinical Lymphoma & Myeloma. 9. S179–S185. 37 indexed citations

20.

Christian, Beth & Thomas S. Lin. (2008). Antibody Therapy for Chronic Lymphocytic Leukemia. Seminars in Hematology. 45(2). 95–103. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact